Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.46 |
| ▸ | HTR2A | P28223 | 4/20 | 0.46 |
| ▸ | HTR2C | P28335 | 4/20 | 0.46 |
| ▸ | HTR2B | P41595 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7414839 | 1.00 | SIGMAR1 (0.46) | SIGMAR1HTR2AHTR2CHTR2BKDM4E | |
| SCHEMBL7407659 | 1.00 | SIGMAR1 (0.46) | SIGMAR1HTR2AHTR2CHTR2BKDM4E | |
| SCHEMBL7415278 | 0.96 | SIGMAR1 (0.42) | SIGMAR1HTR2AHTR2CHTR2BKDM4E | |
| SCHEMBL7415285 | 0.96 | SIGMAR1 (0.42) | SIGMAR1HTR2AHTR2CHTR2BKDM4E | |
| SCHEMBL7078130 | 0.96 | SIGMAR1 (0.47) | SIGMAR1HTR2AHTR2CHTR2BKDM4E | |
| SCHEMBL7078706 | 0.96 | SIGMAR1 (0.47) | SIGMAR1HTR2AHTR2CHTR2BKDM4E | |
| SCHEMBL7415431 | 0.96 | SIGMAR1 (0.47) | SIGMAR1HTR2AHTR2CHTR2BKDM4E | |
| SCHEMBL7078128 | 0.96 | SIGMAR1 (0.47) | SIGMAR1HTR2AHTR2CHTR2BKDM4E | |
| SCHEMBL7078708 | 0.96 | SIGMAR1 (0.47) | SIGMAR1HTR2AHTR2CHTR2BKDM4E | |
| SCHEMBL7409859 | 0.92 | SIGMAR1 (0.43) | SIGMAR1HTR2AHTR2CHTR2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0734379-B1 | 2-ARYLALKENYL-AZACYCLOALKANE DERIVATIVES AS SIGMA RECEPTOR LIGANDS, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF | PARKE DAVIS (FR) | 2001-03-07 | — | — | EP | claimed |
| US-6440997-B2 | CARRYING OUT THE RESOLUTION OF (+/-) E-2-(3,4-DICHLOROCINNAMYL)PIPERIDINE VIA THE EUTOMERIC DIASTEREOISOMERIC SALT WITH N-ACETYL-L-PHENYLALANINE, ACYLATING, REDUCING WITH CYCLOPROPANECARBONYL CHLORIDE | WARNER-LAMBERT COMPANY | 2002-08-27 | — | — | US | disclosed |
| US-20010008897-A1 | Carrying out the resolution of (+/-) E-2-(3,4-dichlorocinnamyl)piperidine via the eutomeric diastereoisomeric salt with N-acetyl-L-phenylalanine, acylating, reducing with cyclopropanecarbonyl chloride | WARNER-LAMBERT COMPANY | 2001-07-19 | — | — | US | disclosed |
| EP-0734379-B1 | 2-ARYLALKENYL-AZACYCLOALKANE DERIVATIVES AS SIGMA RECEPTOR LIGANDS, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF | PARKE DAVIS (FR) | 2001-03-07 | — | — | EP | disclosed |
| EP-0995436-A2 | Ligands for sigma receptors and their therapeutical applications | PARKE-DAVIS (FR) | 2000-04-26 | — | — | EP | disclosed |
| US-6013656-A | PSYCHOLOGICAL DISORDERS; GASTROINTESTINAL DISORDERS; NERVOUSSYSTEM DISORDERS | WARNER-LAMBERT COMPANY (US) | 2000-01-11 | — | — | US | disclosed |
| US-5849760-A | 2-(arylalkenyl)azacycloalkane derivatives as ligands for sigma receptors | INSTITUT DE RECHERCHE JOUVEINAL (FR) | 1998-12-15 | — | — | US | disclosed |
| WO-1995015948-A1 | NOVEL 2-ARYLALKENYL-AZACYCLOALKANE DERIVATIVES AS SIGMA RECEPTOR LIGANDS, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF | INSTITUT DE RECHERCHE JOUVEINAL (FR) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008897-A1 | Carrying out the resolution of (+/-) E-2-(3,4-dichlorocinnamyl)piperidine via the eutomeric diastereoisomeric salt with N-acetyl-L-phenylalanine, acylating, reducing with cyclopropanecarbonyl chloride | DNPEP, NAT1, NAALAD2 | SIGMAR1 1334/4885HTR2A 1987/4885HTR2C 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.